Clinuvel Pharmaceuticals Limited
CLVLF
$7.96
-$0.1583-1.95%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 26.98% | 20.82% | 13.48% | 10.81% | 9.18% |
| Total Depreciation and Amortization | 18.43% | 30.08% | 42.62% | 35.03% | 28.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -167.49% | -113.11% | -25.53% | 58.30% | 235.36% |
| Change in Net Operating Assets | -95.12% | -95.12% | -95.12% | -200.66% | -125.27% |
| Cash from Operations | -43.80% | -23.81% | -2.33% | -5.58% | -7.77% |
| Capital Expenditure | 94.37% | 15.93% | -426.38% | -510.97% | -624.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -116.21% | -30.90% | 25.72% | 20.09% | 11.24% |
| Cash from Investing | -67.80% | -25.26% | 11.11% | 2.26% | -11.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -43.30% | -37.45% | -31.71% | -6.02% | 16.01% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.52% | -12.68% | -21.72% | -21.72% | -21.72% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -43.52% | -50.83% | -55.56% | -36.06% | -16.94% |
| Foreign Exchange rate Adjustments | 534.13% | -101.56% | -166.78% | -133.11% | -86.18% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -254.97% | -200.81% | -29.60% | -34.05% | -34.87% |